Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has market cap of $2.40 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
Analysts expect Alexco Resource Corp. (USA) (NYSEMKT:AXU) to report $0.00 EPS on March, 22. The stock increased 0.64% or $0.01 on March 20, reaching $1.57. About shares traded. Alexco Resource Corp. (USA) (NYSEMKT:AXU) has declined 29.28% since August 12, 2016 and is downtrending. It has underperformed by 37.95% the S&P500.
Alexco Resource Corp. operates two businesses: a mining business, consisting of mineral exploration and mine development and operation in Canada, located in Yukon Territory, and through its Alexco Environmental Group (AEG), an environmental services business, providing consulting, remediation solutions and project management services in respect of environmental permitting and compliance and site remediation, in Canada and the United States. The company has market cap of $140.98 million. The Company’s principal mining business activities are being carried out within the Keno Hill Silver District (KHSD) in Yukon Territory. It currently has negative earnings. The KHSD project is located near the village of Keno City, approximately 350 kilometers north of Whitehorse, Yukon.
The stock decreased 0.44% or $0.1 during the last trading session, reaching $22.85. About shares traded. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 30.04% since August 12, 2016 and is downtrending. It has underperformed by 38.71% the S&P500.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on May, 8. They expect $-0.66 earnings per share, up 16.46% or $0.13 from last year’s $-0.79 per share. After $-0.66 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
